<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961334</url>
  </required_header>
  <id_info>
    <org_study_id>MOSES</org_study_id>
    <nct_id>NCT03961334</nct_id>
  </id_info>
  <brief_title>MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention</brief_title>
  <acronym>MOSES</acronym>
  <official_title>MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial is addressing the question if a biologically distinct subgroup of ischemic&#xD;
      stroke patients without known atrial fibrillation at admission, selected by a cut-off level&#xD;
      of MRproANP concentration, which represents a underlying increased risk of cardiac&#xD;
      thrombogenicity, benefits from direct oral anticoagulation (DOAC) versus antiplatelets as&#xD;
      preventive treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three DOACs with marketing authorisation in Switzerland and the EU for the prevention of&#xD;
      stroke and systemic embolism in patients with atrial fibrillation can be used. Eligible&#xD;
      patients will be randomly assigned to either the control (antiplatelet) or the experimental&#xD;
      (DOAC) arm with a ratio of 1:1. Each study participant will be observed during a follow up&#xD;
      period within one year after index stroke.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Blinded endpoint assessment by independent CEC</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent stroke of any type</measure>
    <time_frame>within one year after index stroke</time_frame>
    <description>The primary outcome measure is the time to any recurrent stroke (ischemic, hemorrhagic, unspecified, or fatal stroke)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of major bleeding, recurrent stroke and/or vascular death</measure>
    <time_frame>within one year after index stroke</time_frame>
    <description>Composite of major bleeding, recurrent stroke and/or vascular death (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding, recurrent stroke and/or vascular death as single components</measure>
    <time_frame>within one year after index stroke</time_frame>
    <description>Each single component of the composite in outcome 2 (major bleeding, recurrent stroke and/or vascular death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">590</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>DOACs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct oral anticoagulants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiplatelets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiplatelets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>150mg 2x/d</description>
    <arm_group_label>DOACs</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>5mg 2x/d</description>
    <arm_group_label>DOACs</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>60mg 1x/d</description>
    <arm_group_label>DOACs</arm_group_label>
    <other_name>Lixiana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>100mg 1x/d</description>
    <arm_group_label>Antiplatelets</arm_group_label>
    <other_name>Aspirin cardio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75mg 1x/d</description>
    <arm_group_label>Antiplatelets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of ischemic stroke&#xD;
&#xD;
          -  elevated MRproANP level within 24 hours from symptom onset&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of AF, AF on 12-lead ECG on admission or any AF ≥30 seconds during&#xD;
             heart-rhythm monitoring prior to randomization&#xD;
&#xD;
          -  Other condition that require anticoagulant therapy (e.g., venous thromboembolism) as&#xD;
             per Investigator's judgment including therapeutical dose of low-molecular-weight&#xD;
             heparin or heparin&#xD;
&#xD;
          -  Strong likelihood to be treated with prolonged (i.e. more than 30 days) dual&#xD;
             antiplatelet therapy during the course of the trial (such as coronary stenting, etc.)&#xD;
&#xD;
          -  Patients undergoing planned procedures where therapy with a DOAC is a contraindication&#xD;
             (e.g. surgery)&#xD;
&#xD;
          -  Previous intracranial hemorrhage in the last year&#xD;
&#xD;
          -  Evidence of severe cerebral amyloid angiopathy if MRI scan performed&#xD;
&#xD;
          -  Chronic kidney disease with creatinin clearance &lt;30ml/min and or subject who requires&#xD;
             haemodialysis or peritoneal dialysis&#xD;
&#xD;
          -  Known bleeding diathesis (e.g. active peptic ulcer disease , platelet count &lt;&#xD;
             100'000/mm3 or haemoglobin &lt; 9 g/dl or INR ≥ 1.7, documented haemorrhagic tendencies&#xD;
             or blood dyscrasias)&#xD;
&#xD;
          -  Active infective endocarditis&#xD;
&#xD;
          -  CT or MRI evidence of cerebral vasculitis&#xD;
&#xD;
          -  Known allergy or intolerance to antiplatelets or DOACs&#xD;
&#xD;
          -  Female who is pregnant or lactating or has a positive pregnancy test at time of&#xD;
             admission&#xD;
&#xD;
          -  Current participation in another drug trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mira Katan, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mira Katan, PD Dr. med.</last_name>
    <phone>+41 44 255 47 32</phone>
    <email>mira.katan@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Götz Thomalla, MD</last_name>
      <email>thomalla@uke.de</email>
    </contact>
    <investigator>
      <last_name>Götz Thomalla, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital - Ullevål</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Else Charlotte Sandset, Dr. med.</last_name>
      <email>else@sandset.net</email>
    </contact>
    <investigator>
      <last_name>Else Charlotte Sandset, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Montaner, MD</last_name>
      <email>jmontaner-ibis@us.es</email>
    </contact>
    <investigator>
      <last_name>Joan Montaner, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Montaner, MD</last_name>
      <email>jmontaner-ibis@us.es</email>
    </contact>
    <investigator>
      <last_name>Joan Montaner, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Campus Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Montaner, MD</last_name>
      <email>jmontaner-ibis@us.es</email>
    </contact>
    <investigator>
      <last_name>Joan Montaner, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau, Department of Neurology</name>
      <address>
        <city>Aarau</city>
        <state>Argau</state>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timo Kahles, MD</last_name>
      <email>timo.kahles@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Timo Kahles, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Marco De Marchis, MD</last_name>
      <email>gian.demarchis@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Gian Marco De Marchis, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bern/Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urs Fischer, MD</last_name>
      <email>urs.fischer@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Urs Fischer, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Cereda, MD</last_name>
      <email>carlo.cereda@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Carlo Cereda, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zurich, Department of Neurology</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mira Katan, PD Dr. med.</last_name>
      <email>mira.katan@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Mira Katan, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesse Dawson, MD</last_name>
      <email>jesse.dawson@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Jesse Dawson, Prof.Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Mira Katan</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

